Identification of polypharmacy patterns in new‐users of metformin using the Apriori algorithm: A novel framework for investigating concomitant drug utilization through association rule mining

Faquetti, Maria Luisa; Torre, Adrián Martínez-De la; Burkard, Theresa; Obozinski, Guillaume; Burden, Andrea M.

doi:10.1002/pds.5583

Cited by 2 publications

(3 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We leveraged an existing cohort of patients with T2DM and polypharmacy, which is described in detail elsewhere 18 . Polypharmacy was defined as the prescription of ≥5 different drug compounds (ie, ≥4 drugs + NIAD) on or within 90 days before the index date.…”

Section: Methodsmentioning

confidence: 99%

“…We leveraged an existing cohort of patients with T2DM and polypharmacy, which is described in detail elsewhere. 18 Polypharmacy was defined as the prescription of ≥5 different drug compounds (ie, ≥4 drugs + NIAD) on or within 90 days before the index date. We identified patients with polypharmacy at the start of NIAD therapy and only considered drugs and diagnoses (ie, history of comorbidities and medical conditions) with a valid flag in the database.…”

Section: Polypharmacy Definitionmentioning

confidence: 99%

See 1 more Smart Citation

Prevalence of potentially inappropriate medications among newly treated patients with type 2 diabetes in UK primary care

Faquetti,

Frey,

Stämpfli

et al. 2024

Brit J Clinical Pharma

Self Cite

View full text Add to dashboard Cite

AimsThe aim of this study was to estimate the prevalence of potentially inappropriate prescriptions (PIPs) in patients starting their first noninsulin antidiabetic treatment (NIAD) using two explicit process measures of the appropriateness of prescribing in UK primary care, stratified by age and polypharmacy status.MethodsA descriptive cohort study between 2016 and 2019 was conducted to assess PIPs in patients aged ≥45 years at the start of their first NIAD, stratified by age and polypharmacy status. The American Geriatrics Society Beers criteria 2015 was used for older (≥65 years) patients and the Prescribing Optimally in Middle‐age People's Treatments criteria was used for middle‐aged (45‐64 years) patients. Prevalence of overall PIPs and individual PIPs criteria was reported using the IQVIA Medical Research Data incorporating THIN, a Cegedim Database of anonymized electronic health records in the UK.ResultsAmong 28 604 patients initiating NIADs, 18 494 (64.7%) received polypharmacy. In older and middle‐aged patients with polypharmacy, 39.6% and 22.7%, respectively, received ≥1 PIP. At the individual PIP level, long‐term proton pump inhibitors (PPI) use was the most frequent PIP among older adults, and strong opioid without laxatives was the most frequent PIP in middle‐aged patients with polypharmacy (11.1% and 4.1%, respectively).ConclusionsThis study revealed that patients starting NIAD treatment receiving polypharmacy have the potential for pharmacotherapy optimization.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Polypharmacy Definitionmentioning

confidence: 99%

Prevalence of potentially inappropriate medications among newly treated patients with type 2 diabetes in UK primary care

Faquetti,

Frey,

Stämpfli

et al. 2024

Brit J Clinical Pharma

Self Cite

View full text Add to dashboard Cite

show abstract

“…We leveraged an existing cohort of patients with T2DM and polypharmacy, which is described in detail elsewhere. [18] In brief, polypharmacy was defined as the prescription of ≥5 different drug compounds on or within 90 days before the index date. We identified patients with polypharmacy at the start of NIAD therapy and only considered drugs and diagnoses (i.e., history of comorbidities and medical conditions in the Beers or PROMPT criteria for assessing PIP) with a valid flag in the database.…”

Section: Polypharmacy Definitionmentioning

confidence: 99%

Examining inappropriate medication in UK primary care for type 2 diabetes patients with polypharmacy

Faquetti

Frey

Stämpfli

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

Aims:To estimate the prevalence of potentially inappropriate prescriptions (PIPs) in patients starting their first non-insulin antidiabetic treatment (NIAD) using two explicit process measures of the appropriateness of prescribing in UK primary care, stratified by age and polypharmacy status.Methods:A descriptive cohort study between 2016 and 2019 was conducted to assess PIPs in patients aged ≥45 years at the start of their first NIAD, stratified by age and polypharmacy status. The American Geriatrics Society (AGS) Beers criteria 2015 was used for older (≥65 years) and the Prescribing Optimally in Middle-age People's Treatments (PROMPT) criteria for middle-aged (45-64 years) patients. Prevalence of overall PIPs and individual PIPs criteria was reported using the IQVIA Medical Research Data incorporating THIN, a Cegedim Database of anonymised electronic health records in the UK.Results:Among 28,604 patients initiating NIADs, 18,494 (64.7%) received polypharmacy. In older and middle-aged patients with polypharmacy, 39.6% and 22.7%, respectively, received ≥1 PIPs. At the individual PIPs level, long-term PPI use and strong opioid without laxatives were the most frequent PIPs among older and middle-aged patients with polypharmacy (11.1% and 4.1%, respectively).Conclusions:This study revealed that patients starting NIAD treatment receiving polypharmacy have the potential for pharmacotherapy optimisation.

show abstract

Identification of polypharmacy patterns in new‐users of metformin using the Apriori algorithm: A novel framework for investigating concomitant drug utilization through association rule mining

Cited by 2 publications

References 48 publications

Prevalence of potentially inappropriate medications among newly treated patients with type 2 diabetes in UK primary care

Prevalence of potentially inappropriate medications among newly treated patients with type 2 diabetes in UK primary care

Examining inappropriate medication in UK primary care for type 2 diabetes patients with polypharmacy

Contact Info

Product

Resources

About